title: A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.
abstract: 67 patients with relapsed or resistant multiple myeloma were randomized to receive either VAD (vincristine, doxorubicin, dexamethasone) or MOD (mitozantrone, vincristine, dexamethasone). 12/30 (40%) patients receiving VAD and 15/37 (41%) patients receiving MOD achieved plateaux. The median duration of plateaux was significantly longer on VAD (15 months) than on MOD (8 months). No significant difference in overall survival was seen between the two treatment arms. The only toxicity which was severe in more than 5% of treatment cycles on either treatment arm was myelosuppression. No toxicity was significantly more severe on MOD than VAD. However, hair loss was significantly more severe on VAD than MOD. The frequencies of thrombocytopenia, haematuria and cutaneous toxicity were significantly greater on VAD than on MOD. Raised serum direct bilirubin levels were seen significantly more often on MOD than VAD. MOD and VAD have similar efficacy in relapsed/resistant multiple myeloma. MOD is the less toxic of the two regimens.
authors.affiliation: Department of Haematology, Liverpool University, UK.
authors.forename: J K
authors.initials: JK
authors.lastname: Phillips
authors.forename: C
authors.initials: C
authors.lastname: Sherlaw-Johnson
authors.forename: R
authors.initials: R
authors.lastname: Pearce
authors.forename: J M
authors.initials: JM
authors.lastname: Davies
authors.forename: J T
authors.initials: JT
authors.lastname: Reilly
authors.forename: A C
authors.initials: AC
authors.lastname: Newland
authors.forename: J C
authors.initials: JC
authors.lastname: Cawley
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006333:Heart Failure / Q000139:chemically induced / Q000401:mortality; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D009503:Neutropenia / Q000139:chemically induced; D012008:Recurrence; D018805:Sepsis / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D007136:Immunoglobulins; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D008942:Mitoxantrone